The study below [1] is a cell study from last year. I don't think it has been posted before.
As many here know, a common reason for resistance to Zytiga or Xtandi is selection for androgen receptor [AR] splice variant dominance, particularly for AR-V7.
AR-V7 is AR without the bit where the androgen binds (the C-terminal ligand binding domain). & yet it somehow remains functional & participates in cell division.
In the study, AR-V7 was seen to induce activation on NF-kB (Nuclear Factor-kappaB), & activated NF-kB in turn was able to induce AR-V7 expression. Melatonin inhibited NF-kB.
Frankly, it's rare for NF-kB to not be activated in serious PCa. All of the common polyphenols that I have written about are NF-kB inhibitors. NF-kB induces many cell survival proteins, including the pro-inflammatory COX/LOX enzymes. Inhibition of NF-kB is a must IMO.
"Here, we showed that in LNCaP and 22Rv1 prostate cancer cells transiently overexpressing androgen receptor splice variant-7 (AR-V7), nuclear factor-kappa B (NF-κB) was activated and could result in up-regulated interleukin (IL)-6 gene expression, indicating a positive interaction between AR-V7 expression and activated NF-κB/IL-6 signaling in castration-resistant prostate cancer (CRPC) pathogenesis. Importantly, both AR-V7-induced NF-κB activation and IL-6 gene transcription in LNCaP and 22Rv1 cells could be inhibited by melatonin. Furthermore, stimulation of AR-V7 mRNA expression in LNCaP cells by betulinic acid, a pharmacological NF-κB activator, was reduced by melatonin treatment. Our data support the presence of bi-directional positive interactions between AR-V7 expression and NF-κB activation in CRPC pathogenesis. Of note, melatonin, by inhibiting NF-κB activation via the previously-reported MT1 receptor-mediated antiproliferative pathway, can disrupt these bi-directional positive interactions between AR-V7 and NF-κB and thereby delay the development of castration resistance in advanced prostate cancer."
-Patrick